Amyloid plaques are still main target for Alzheimer’s drugsBMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i214 (Published 13 January 2016) Cite this as: BMJ 2016;352:i214
- Nigel Hawkes
John Hardy, the UK geneticist behind the amyloid hypothesis of Alzheimer’s disease, still believes that drugs targeted at the amyloid plaques formed in the brain may slow progression of the disease despite previous disappointing trial results.
Giving the New Year lecture at the University College London School of Pharmacy on 12 January, Hardy was optimistic that a new trial of Eli Lilly’s drug solanezumab or a recently launched trial of Biogen’s aducanumab would produce positive results.
“We’re hopeful, but we don’t want to overstate or mislead people,” he said. “These trials will report in about 18 months, and if they are successful it tells us immediately we’re on the right road and that will lead a massive investment by those two companies and …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial